Funding JOINT TRANSNATIONAL CALL 2021 Funding programme, Funded by: Horizon 2020, Submission deadline: 04/03/2021 https:////www.gesundheitsindustrie-bw.de:443/en/database/funding/joint-transnational-call-2021
Press release - 20/10/2020 EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment The European Investment Bank (EIB) and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement today to facilitate the company’s development and clinical testing of a novel therapy treating severe respiratory infections with RNA viruses. RNA viruses cause diseases such as influenza, SARS and COVID-19. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/eib-backs-atriva-therapeutics-eur24-million-development-potential-covid-19-treatment
Press release - 25/09/2020 Bosch’s new rapid coronavirus test delivers reliable results in 39 minutes Bosch has developed a new rapid test for its Vivalytic analysis device to detect the SARS-CoV-2 pathogen. The test provides a reliable result in 39 minutes and is currently the fastest polymerase chain reaction (PCR) test worldwide.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/boschs-new-rapid-coronavirus-test-delivers-reliable-results-39-minutes
Press release - 07/09/2020 Cyber Valley launches Investor Network Europe’s largest AI research consortium attracts interest from some of the world’s most successful venture capital firms.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/cyber-valley-gruendet-investor-network
Innovations in the field of endoscopy - 08/06/2020 Gastroscopies with pill cameras A pill camera to examine the gastrointestinal tract that can be swallowed without major difficulty, controlled intuitively from the outside and deliver images in real time - why would any doctor or patient say no? To non-experts, it sounds more like science fiction but such a device is actually already in development: since 2019, Tübingen-based Ovesco Endoscopy AG and three partners have been working together on this in a project called nuEndo.https:////www.gesundheitsindustrie-bw.de/en/article/news/magenspiegelung-kamerapille
Translational oncology - 26/05/2020 Translation: driver of cancer medicine The fight against cancer is a pressing issue. Although technological advances in the treatment, prevention and early detection of cancer have improved over the past few decades, the number of people affected is increasing. Cancer medicine now wants to counteract this by joining forces with other players involved in the field. https:////www.gesundheitsindustrie-bw.de/en/article/news/translation-driver-cancer-medicine
Prime Vector Technologies GmbH - 09/04/2020 A modular brick system for developing a COVID-19 vaccine Prime Vector Technologies GmbH (PVT), a start-up company based in Tübingen in southern Germany, uses a modular brick system to develop vaccines against cancer and infectious diseases. The PVT team is currently working flat out to develop a COVID-19 vaccine.https:////www.gesundheitsindustrie-bw.de/en/article/news/mit-einem-impfstoffbaukasten-gegen-covid-19
Expert interview on NTDs – part 2 - 29/05/2019 Neglected tropical diseases - Gisela Schneider: the burden of disease "Leaving no one behind". The motto of the 2030 Agenda with its 17 Sustainable Development Goals (SDGs) which was signed by the United Nations (UN) in 2015 makes clear that combatting poverty and its consequences is an essential part of sustainable development. The fight against neglected tropical diseases (NTDs) is defined as a major aim of the Agenda’s sustainable development goals. The World Health Organisation (WHO) regards twenty…https:////www.gesundheitsindustrie-bw.de/en/article/news/neglected-tropical-diseases-gisela-schneider-the-burden-of-disease
Expert interview on NTDs – part 1 - 11/04/2019 Neglected tropical diseases – Carsten Köhler: impulses from Baden-Württemberg More than one billion people worldwide suffer from neglected tropical diseases (NTDs). NTDs are mostly poverty-related infectious diseases that prevail in tropical countries due to lack of research and measures to detect, prevent and control them. Dr. Dr. Carsten Köhler reports on the political, economic and scientific contributions Germany and Baden-Württemberg can make to successfully change this situation.https:////www.gesundheitsindustrie-bw.de/en/article/news/vernachlaessigte-tropenkrankheiten-carsten-koehler-impulse-aus-baden-wuerttemberg
Article - 10/01/2019 Stocktaking and recommendations for action: the BBAW’s fourth gene technology report In the new gene technology report, the interdisciplinary working group of the Berlin-Brandenburg Academy of Sciences (BBAW) takes stock of gene technology developments in Germany during the past few decades, and discusses the societal, legal and ethical challenges associated with these technologies in the future. The report is highly topical due to the controversy surrounding the ruling of the European Court of Justice on CRISPR/Cas9 genome…https:////www.gesundheitsindustrie-bw.de/en/article/news/stocktaking-and-recommendations-for-action-the-bbaws-fourth-gene-technology-report
Anniversary - 12/12/2018 15 years of BIOPRO: Pooling competencies – pushing innovations This is the leitmotif of BIOPRO Baden-Württemberg GmbH, which was founded in 2003. 15 years is a good time to pause for a moment and take a look at BIOPRO’s work and achievements. As a central point of contact and wholly-owned subsidiary of the Baden-Württemberg government whose main objective is to promote networking, BIOPRO knows only too well that progress is not made alone, but in collaboration with others.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/15-years-of-biopro-pooling-competencies-pushing-innovations
Press release - 10/12/2018 High distinction for stem cell researcher Andreas Trumpp This year's State Research Prize of Baden-Württemberg awarded for outstanding achievements in applied research goes to Andreas Trumpp from the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM). Theresia Bauer, State Minister of Science, Research and the Arts, presented the award, which carries a monetary prize of €100.000, at a festive ceremony on December 10, 2018.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/high-distinction-for-stem-cell-researcher-andreas-trumpp
Article - 30/10/2018 Eucor – bringing the European Campus to life Enrolling at one university and being able to use the services of a total of five universities is unique in the European Research Area. A model project called Eucor - The European Campus offers students and young scientists this opportunity at universities in the Germany-France-Switzerland border triangle, which simultaneously acts as a borderless academic area for the sciences. https:////www.gesundheitsindustrie-bw.de/en/article/news/eucor-bringing-the-european-campus-to-life
Press release - 27/09/2018 Three new Clusters of Excellence for Tübingen University takes next hurdle in the German government’s Excellence Strategy funding program. The University of Tübingen is to have three new Clusters of Excellence.As part of the German government’s Excellence Strategy funding forhigher education research, Tübingen will host new outstanding research networks starting in January 2019. Representatives of Germany’s higher education policymakers announced the decision in Bonn on Thursday.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/three-new-clusters-of-excellence-for-tuebingen
Press release - 27/07/2018 KIT Takes the Next Step: Federal and State Ministries Determined to Push KIT’s Further Development To further support and develop the scientific capacity of Karlsruhe Institute of Technology (KIT), the federal and state governments are determined to take the courageous merger of 2009 to the next level. During their joint visit of KIT today, Federal Minister of Education and Research Anja Karliczek and the Baden-Württemberg Minister for Science, Research and the Arts Theresia Bauer agreed on the next steps. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/kit-takes-the-next-step-federal-and-state-ministries-determined-to-push-kits-further-development
Article - 05/04/2018 Crossing the valley of death with translational cancer research It can take many decades before promising research results become therapies that have a positive effect on cancer patients. Most research projects go adrift somewhere between the laboratory and the bedside in the so-called "valley of death". Projects carried out at the DKFZ show that translational cancer research actually works.https:////www.gesundheitsindustrie-bw.de/en/article/news/crossing-the-valley-of-death-with-translational-cancer-research
Article - 14/03/2018 Patent versus publication: setting up start-ups in the sciences When it comes to universities as start-up incubators, the Massachusetts Institute of Technology (MIT) in the USA is often used as a prime example of entrepreneurial impact. Well over 100 high-tech spin-offs have been set up in the vicinity of the renowned university. Many German universities also offer attractive conditions for scientists with an entrepreneurial spirit. https:////www.gesundheitsindustrie-bw.de/en/article/news/patent-versus-publication-setting-up-start-ups-in-the-sciences
Press release - 21/02/2018 German Cancer Award for Michael Baumann Michael Baumann, Chairman and Scientific Director of the German Cancer Research Center (DKFZ) in Heidelberg, receives the 2017 German Cancer Award in the category "Translational Research". The science award, which is sponsored by the German Cancer Society and the German Cancer Foundation, is one of the most prestigious distinctions in cancer medicine in Germany.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/german-cancer-award-for-michael-baumann
Article - 14/02/2018 Animal-free diabetes research with the pancreas chip Quite a number of promising drug candidates for the treatment of diabetes are currently in the pharmaceutical pipeline, including innovative drugs that can stimulate the regeneration of insulin-producing pancreatic cells. However, they will have to be safety tested in animals. Scientists from Ulm University Hospital have now begun to develop a pancreatic chip from stem cells.https:////www.gesundheitsindustrie-bw.de/en/article/news/animal-free-diabetes-research-with-the-pancreas-chip
Big Data - 14/12/2017 Looking at the whole genome raises new questions Research laboratories around the world have long focused on studying the whole human genome. It is hoped that knowing the whole human genome will improve diagnostics and enable more specific therapies. Although genome analysis has not yet reached routine clinical application, whole genome sequencing has already raised many ethical and legal issues - for researchers, physicians and patients.https:////www.gesundheitsindustrie-bw.de/en/article/news/looking-at-the-whole-genome-raises-new-questions
Press release - 12/12/2017 BRAIN AG and Mannheim University develop 3D skin models for health care and cosmetics Research collaboration in project M2Aind for new real-time and high-resolution screening technologies of 3D skin spheroids. Mannheim University of Applied Sciences builds on expertise in 3D cell culture and advanced live cell imaging. BRAIN contributes unique skin reporter cells, screening compound libraries and market knowledge. Review article in Journal of Cellular Biotechnology. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/brain-ag-and-mannheim-university-develop-3d-skin-models-for-health-care-and-cosmetics
Press release - 01/12/2017 Berlin-Brandenburg Academy Prize for Lena Maier-Hein Lena Maier-Hein from the German Cancer Research Center (DKFZ) helps physicians get better vision during minimally-invasive surgery. Using novel methods of image analysis, she wants to provide additional image information for surgeons. Thus, they can better differentiate tumors from healthy tissue and execute safer surgical tumor therapies. Maier-Hein now receives the Prize of the Berlin-Brandenburg Academy of Sciences and Humanities, which is…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/berlin-brandenburg-academy-prize-for-lena-maier-hein
Article - 27/11/2017 Antimicrobial layer expected to fight hospital acquired infections Infections caused by bacteria that contaminate the surface of medical devices such as catheters and wound dressings are not that rare and can even be life-threatening. However, at present there is no really effective way to keep these products germ-free until they are used. Scientists at the University of Freiburg have now developed a surface coating that reliably kills bacteria, but is harmless to human cells.https:////www.gesundheitsindustrie-bw.de/en/article/news/antimicrobial-layer-expected-to-fight-hospital-acquired-infections
Expert interview - 02/08/2017 Innovative diagnosis and treatment methods – regulation of their reimbursement in the German healthcare sector The German healthcare cost reimbursement system differentiates between in- and outpatient medical products. In an interview with Caroline Ref and Jasmin Dabrowski from BIOPRO Baden-Württemberg, Michael Weißer, Chief Operating Officer of AiM GmbH in Lörrach, gives interesting insights into the reimbursement of medical care products, in particular with regard to the introduction of new and innovative diagnosis and treatment methods. https:////www.gesundheitsindustrie-bw.de/en/article/news/innovative-diagnosis-and-treatment-methods-regulation-of-their-reimbursement-in-the-german-healthcare-sector
Press release - 24/05/2017 High-Tech Gründerfonds (HTGF) invests in Reutlingen-based SIGNATOPE GmbH – Safe medications thanks to new test procedures High-Tech Gründerfonds is investing EUR 600,000 in Reutlingen-based SIGNATOPE GmbH. SIGNATOPE will use the funds to advance the development of its unique biomarker assay system, that has been established to support pharmaceutical research. The technology is based on special antibodies and allows the early detection of possible side effects during the drug development process. Thereby, the need for animal testing will be reduced while the drug…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/high-tech-gruenderfonds-htgf-invests-in-reutlingen-based-signatope-gmbh-safe-medications-thanks-to-new-test-procedures